Table 2.
Baseline | 8 Weeks | 16 Weeks | 24 Weeks | 52 Weeks | |
---|---|---|---|---|---|
Clinically eligible patients | 508 | 508 | 508 | 508 | 508 |
Withdrawn consent (entire protocol) | 9 (2%) | 43 (8%) | 53 (10%) | 55 (11%) | 55 (11%) |
Inevaluable, patient death | 2 (0.4%) | 14 (3%) | 109 (21%) | 173 (34%) | 271 (53%) |
Evaluable patients | 497 | 451 | 346 | 280 | 182 |
Analyzable | 470 (95%) | 266 (59%) | 179 (52%) | 149 (53%) | 79 (43%) |
Not analyzable | 27 (5%) | 185 (41%) | 167 (48%) | 131 (47%) | 103 (57%) |